NCT01652742已完成1 期
Pharmacokinetics and Pharmacodynamics of BI 135585 XX Administered as Oral Dose in Healthy Male Volunteers (Open-label, Single-dose Trial)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Cmax (maximum measured concentration of the analyte in plasma)
研究概览
简要总结
To investigate the pharmacokinetics and pharmacodynamics of BI 135585 XX following single dose administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
BI 135585 XX
Experimental
one single dose
干预措施: BI 135585 XX (Drug)
结局指标
主要结局
Cmax (maximum measured concentration of the analyte in plasma)
时间窗: up to 4 days postdose
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)
时间窗: up to 4 days postdose
次要结局
- AUC0-8 of BI 135585 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(up to 4 days postdose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese VolunteersHealthyNCT02183532Boehringer Ingelheim12
已完成
1 期
Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male VolunteersHealthyNCT02183389Boehringer Ingelheim18
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male VolunteersHealthyNCT02183298Boehringer Ingelheim36
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT02183415Boehringer Ingelheim77
已完成
1 期
To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male VolunteersHealthyNCT02706925Boehringer Ingelheim63